Cargando…

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to control, and patients with high-risk factors p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Ying, Liu, Yao, Liu, Long, Jiang, Yuyong, Hou, Yixin, Zhou, Yang, Song, Rui, Chen, Xiaoyou, Wang, Xianbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426238/ https://www.ncbi.nlm.nih.gov/pubmed/36052136 http://dx.doi.org/10.3389/fphar.2022.978979

Ejemplares similares

Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019
por: Liu, Jingyuan, et al.
Publicado: (2021)

Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway
por: Feng, Ying, et al.
Publicado: (2022)

Jiedu Tongluo Granules Ameliorates Post-stroke Depression Rat Model via Regulating NMDAR/BDNF Signaling Pathway
por: Zhao, Aimei, et al.
Publicado: (2021)

Evaluation of LiangXue JieDu Therapy in Combination With Western Medicine for Acute-On-Chronic Liver Failure: A Systematic Review and meta-Analysis
por: Shi, Ke, et al.
Publicado: (2022)

Prevention of atherosclerosis by Yindan Xinnaotong capsule combined with swimming in rats
por: Wang, Jianlu, et al.
Publicado: (2015)

In Vitro Antibacterial Experiment of Fuzheng Jiedu Huayu Decoction Against Multidrug-Resistant Pseudomonas aeruginosa
por: Xu, Hongri, et al.
Publicado: (2020)

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

The interaction of MD-2 with small molecules in huanglian jiedu decoction play a critical role in the treatment of sepsis
por: Chen, Guirong, et al.
Publicado: (2022)

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
por: Yin, Shengnan, et al.
Publicado: (2022)

A Novel Strategy for Decoding and Validating the Combination Principles of Huanglian Jiedu Decoction From Multi-Scale Perspective
por: Wang, Ke-Xin, et al.
Publicado: (2020)

Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
por: Molina, Kyle C., et al.
Publicado: (2023)

Subchronic toxicity of herbal compound “Jiedu Huayu” granules in rats
por: Wang, Minggang, et al.
Publicado: (2017)

Qingfei Jiedu Granules fight influenza by regulating inflammation, immunity, metabolism, and gut microbiota
por: Cui, Xuran, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Huanglian Jiedu Decoction in the Treatment of the Traditional Chinese Medicine Syndrome “Shanghuo”–An Intervention Study
por: Luo, Keke, et al.
Publicado: (2021)

The Anti-Inflammatory and Anti-Pruritus Mechanisms of Huanglian Jiedu Decoction in the Treatment of Atopic Dermatitis
por: Xu, Yubin, et al.
Publicado: (2021)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma
por: Shi, Ke, et al.
Publicado: (2023)

Liangxue Jiedu Formula Improves Psoriasis and Dyslipidemia Comorbidity via PI3K/Akt/mTOR Pathway
por: Xie, Xinran, et al.
Publicado: (2021)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Yiqi Jiedu Huayu Decoction Alleviates Renal Injury in Rats With Diabetic Nephropathy by Promoting Autophagy
por: Xuan, Chen, et al.
Publicado: (2021)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
por: Lau, Jonathan J., et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Therapeutic Effect and Mechanism of Bushen-Jianpi-Jiedu Decoction Combined with Chemotherapeutic Drugs on Postoperative Colorectal Cancer
por: Yang, Meng-Die, et al.
Publicado: (2021)

New strategies for identifying and masking the bitter taste in traditional herbal medicines: The example of Huanglian Jiedu Decoction
por: Ke, Xiumei, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Uncovering the active constituents and mechanisms of Rujin Jiedu powder for ameliorating LPS-induced acute lung injury using network pharmacology and experimental investigations
por: Ma, Yuhui, et al.
Publicado: (2023)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Study on the Molecular Basis of Huanglian Jiedu Decoction Against Atopic Dermatitis Integrating Chemistry, Biochemistry, and Metabolomics Strategies
por: Chen, Jing, et al.
Publicado: (2021)

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
por: Wang, Yanqun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hice4ruj1gstfqt9plhaq99ke8